Cargando…

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up

BACKGROUND: The currently approved dose of darunavir/ritonavir is 800/100 mg once daily for PI-naïve patients, and 600/100 mg twice daily for PI-pretreated patients. However, in DRV-sensitive patients at baseline in the POWER 1/2 trials, similar rates of HIV RNA suppression (1 log reduction) were ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanzafame, Massimiliano, Lattuada, Emanuela, Rigo, Fabio, Hill, Andrew, Vento, Sandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P290
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225444/ https://www.ncbi.nlm.nih.gov/pubmed/25397566 http://dx.doi.org/10.7448/IAS.17.4.19822

Ejemplares similares

Facteurs pronostiques des pneumonies à SARS-COV-2
por: Zaibi, H., et al.
Publicado: (2022)

Airway Complications After Lung Transplant for Post Coronaviral Disease (COVID-19) Acute Respiratory Distress Syndrome (ARDS) Related End Stage Lung Disease: Single Centre Experience
por: Kumar, S., et al.
Publicado: (2022)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Impact psychologique de l’infection à Covid-19 chez les sujets diabétiques : expérience d’un service de médecine interne
por: Sassi, A., et al.
Publicado: (2023)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Transmitted antiretroviral drug resistance in treatment naïve HIV-infected persons in London in 2011 to 2013
por: McFaul, Katie, et al.
Publicado: (2014)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
por: Dickinson, Laura, et al.
Publicado: (2014)

Determinants of HIV-1 drug resistance in treatment-naïve patients and its clinical implications in an antiretroviral treatment program in Cameroon
por: Zoufaly, Alexander, et al.
Publicado: (2014)

Temporal increase in HIV-1 non-R5 tropism frequency among antiretroviral-naive patients from northern Poland
por: Parczewski, Milosz, et al.
Publicado: (2014)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report
por: Chiesi, Sheila, et al.
Publicado: (2019)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
por: Geretti, Anna Maria, et al.
Publicado: (2015)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
por: Tashima, Karen, et al.
Publicado: (2014)

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review
por: Naccarato, Mark J., et al.
Publicado: (2018)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2016)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
por: Casado, JL, et al.
Publicado: (2010)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
por: Zaccarelli, Mauro, et al.
Publicado: (2014)

Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa
por: Simmons, Bryony, et al.
Publicado: (2014)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Hypovitaminosis D in HIV-infected patients in Lisbon: a link with antiretroviral treatment
por: Boura, Márcia, et al.
Publicado: (2014)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
por: Schultze, Anna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7uvi0g9g4h4nlljqqv5cj157ra